Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine

被引:61
|
作者
Zollinger, Wendell D. [1 ]
Donets, Mikhail A. [1 ]
Schmiel, Deborah H. [1 ]
Pinto, Valerian B. [1 ]
Labrie, Joseph E., III [1 ]
Moran, Elizabeth E. [1 ]
Brandt, Brenda L. [1 ]
Ionin, Boris [1 ]
Marques, Ryan [1 ]
Wu, Max [1 ]
Chen, Ping [1 ]
Stoddard, Mark B. [1 ]
Keiser, Paul B. [1 ]
机构
[1] WRAIR, Div Bacterial & Rickettsial Dis, Silver Spring, MD 20910 USA
关键词
Neisseria meningitidis; Vaccine; Vesicles; MENINGITIDIS SEROGROUP-B; LIPOPOLYSACCHARIDE CORE OLIGOSACCHARIDES; SYNERGISTIC BACTERICIDAL ACTIVITY; NEISSERIA-MENINGITIDIS; MONOCLONAL-ANTIBODIES; PROTEIN; IMMUNOGENICITY; DISEASE; POLYSACCHARIDE; CANDIDATE;
D O I
10.1016/j.vaccine.2010.05.006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A vaccine based on native outer membrane vesicles (NOMV) that has potential to provide safe, broad based protection against group B strains of Neisseria meningitidis has been developed. Three antigenically diverse group B strains of N. meningitidis were chosen and genetically modified to improve safety and expression of desirable antigens. Safety was enhanced by disabling three genes: synX, IpxL1, and IgtA. The vaccine strains were genetically configured to have three sets of antigens each with potential to induce protective antibodies against a wide range of group B strains. Preliminary immunogenicity studies with combined NOMV from the three strains confirmed the capacity of the vaccine to induce a broad based bactericidal antibody response. Analysis of the bactericidal activity indicated that antibodies to the LOS were responsible for a major portion of the bactericidal activity and that these antibodies may enhance the bactericidal activity of anti-protein antibodies. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5057 / 5067
页数:11
相关论文
共 50 条
  • [31] Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870
    Hou, VC
    Koeberling, O
    Welsch, JA
    Granoff, DM
    JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (04): : 580 - 590
  • [32] Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys
    van der Voort, ER
    Schuller, M
    Holst, J
    de Vries, P
    van der Ley, P
    van den Dobbelsteen, G
    Poolman, J
    VACCINE, 2000, 18 (14) : 1334 - 1343
  • [33] Antibody avidity and immunoglobulin G Isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine
    Vermont, CL
    van Dijken, HH
    van Limpt, CJP
    de Groot, R
    van Alphen, L
    van den Dobbelsteen, GPJM
    INFECTION AND IMMUNITY, 2002, 70 (02) : 584 - 590
  • [34] Antibody specificities and effect of meningococcal carriage in Icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine
    Wedege, E
    Kuipers, B
    Bolstad, K
    van Dijken, H
    Froholm, LO
    Vermont, C
    Caugant, DA
    van den Dobbelsteen, G
    INFECTION AND IMMUNITY, 2003, 71 (07) : 3775 - 3781
  • [35] A Meningococcal Native Outer Membrane Vesicle Vaccine With Attenuated Endotoxin and Overexpressed Factor H Binding Protein Elicits Gonococcal Bactericidal Antibodies
    Beernink, Peter T.
    Ispasanie, Emma
    Lewis, Lisa A.
    Ram, Sanjay
    Moe, Gregory R.
    Granoff, Dan M.
    JOURNAL OF INFECTIOUS DISEASES, 2019, 219 (07): : 1130 - 1137
  • [36] Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine
    Peeters, CCAM
    Rumke, HC
    Sundermann, LC
    vanderVoort, EMR
    Meulenbelt, J
    Schuller, M
    Kuipers, AJ
    vanderLey, P
    Poolman, JT
    VACCINE, 1996, 14 (10) : 1009 - 1015
  • [37] Identification of immunogenic outer membrane vesicle vaccine antigen components using a meningococcal protein microarray
    Ramirez-Bencomo, F.
    Thistlethwaite, A.
    Viviani, V.
    Bartolini, E.
    Pizza, M.
    Biolchi, A.
    Muzzi, A.
    Delany, I.
    Awanye, A. M.
    Chang, C. M.
    Borrow, R.
    Derrick, J. P.
    VACCINE, 2025, 53
  • [38] Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines
    Sandbu, Synne
    Feiring, Berit
    Oster, Philipp
    Helland, Oddveig S.
    Bakke, Hilde S. W.
    Naess, Lisbeth M.
    Aase, Audun
    Aaberge, Ingeborg S.
    Kristoffersen, Anne-Cathrine
    Rydland, Kjersti M.
    Tilman, Sandrine
    Nokleby, Hanne
    Rosenqvist, Einar
    CLINICAL AND VACCINE IMMUNOLOGY, 2007, 14 (09) : 1062 - 1069
  • [39] Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks
    Taha, Muhamed-Kheir
    Zarantonelli, Maria Leticia
    Alonso, Jean-Michel
    Naess, Lisbeth Meyer
    Holst, Johan
    Feiring, Berit
    Rosenqvist, Einar
    VACCINE, 2007, 25 (14) : 2537 - 2538
  • [40] New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months
    Wong, Sharon
    Lennon, Diana
    Jackson, Catherine
    Stewart, Joanna
    Reid, Stewart
    Crengle, Sue
    Tilman, Sandrine
    Aaberge, Ingeborg
    O'Hallahan, Jane
    Oster, Philipp
    Mulholland, Kim
    Martin, Diana
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2007, 26 (04) : 345 - 350